Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash from Investing Activities (2023 - 2025)

Historic Cash from Investing Activities for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$7000.0.

  • Inhibrx Biosciences' Cash from Investing Activities rose 9716.6% to -$7000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$44000.0, marking a year-over-year increase of 9926.95%. This contributed to the annual value of -$2.6 million for FY2024, which is 4345.74% up from last year.
  • Inhibrx Biosciences' Cash from Investing Activities amounted to -$7000.0 in Q3 2025, which was up 9716.6% from -$21000.0 recorded in Q1 2025.
  • Inhibrx Biosciences' Cash from Investing Activities' 5-year high stood at -$7000.0 during Q3 2025, with a 5-year trough of -$3.4 million in Q4 2023.
  • Its 3-year average for Cash from Investing Activities is -$859750.0, with a median of -$529000.0 in 2023.
  • Within the past 5 years, the most significant YoY rise in Inhibrx Biosciences' Cash from Investing Activities was 9953.52% (2024), while the steepest drop was 6954.38% (2024).
  • Quarter analysis of 3 years shows Inhibrx Biosciences' Cash from Investing Activities stood at -$3.4 million in 2023, then skyrocketed by 99.54% to -$16000.0 in 2024, then soared by 56.25% to -$7000.0 in 2025.
  • Its last three reported values are -$7000.0 in Q3 2025, -$21000.0 for Q1 2025, and -$16000.0 during Q4 2024.